SGLT2i and Primary Prevention of Cancer Therapy–Related Cardiac Dysfunction in Patients With Diabetes
Main finding · CTRCDResult — go to the resultHazard ratio 0.76 95% CI 0.69–0.84Authors' conclusion
SGLT2i administration was associated with a significantly decreased risk of developing CTRCD in patients with T2DM and cancer.
Study context
- Population
- Adults with T2DM and cancer exposed to potentially cardiotoxic antineoplastic agents, without prior cardiomyopathy or HF8,675 matched per cohort
- Participants
- 8,675 vs 8,675
- Exposure
- SGLT2i use vs no SGLT2i use
- SGLT2in = 8,675
- No SGLT2in = 8,675reference
- Outcome
- Cancer therapy-related cardiac dysfunction (CTRCD)
- Follow-up
- 12 months
Methodological detailspropensity-score matched, TriNetX database
- Propensity-score matched
- TriNetX database
Main finding
CTRCD
Hazard ratio
0.76
95% CI 0.69–0.84
SGLT2ivs No SGLT2i
HR 0.76 (95% CI 0.69–0.84)
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| HF exacerbations, all-cause mortality, all-cause hospitalizations/ED visits · 12 monthsSGLT2ivs No SGLT2iHF exacerbations | 0.81 (0.72–0.90) | |
| HF exacerbations, all-cause mortality, all-cause hospitalizations/ED visits · 12 monthsSGLT2ivs No SGLT2iAll-cause mortality | 0.67 (0.61–0.74) | |
| HF exacerbations, all-cause mortality, all-cause hospitalizations/ED visits · 12 monthsSGLT2ivs No SGLT2iAll-cause hospitalizations/ED visits | 0.93 (0.89–0.97) | |
| 0.512Hazard ratio (log scale) |
Cancer therapy-related cardiac dysfunction (CTRCD) by cancer therapy class (subgroups)
- Reduced CTRCD risk across various classes of cancer therapies with SGLT2i
Original publication
SGLT2i and Primary Prevention of Cancer Therapy–Related Cardiac Dysfunction in Patients With Diabetes. JACC CardioOncol. Published 22 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →